Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

BACKGROUND: Sandoz adalimumab SDZ-ADL (GP-2017) is an approved adalimumab biosimilar with similar efficacy and comparable safety and immunogenicity to reference adalimumab (ref-ADL) as confirmed by analytical, pharmacokinetic and confirmatory studies. ADMYRA, a phase III double-blind study, was cond...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiland, Piotr, Jeka, Sławomir, Dokoupilová, Eva, Brandt-Jürgens, Jan, Miranda Limón, Juan Manuel, Cantalejo Moreira, Miguel, Cabello, Raul Veiga, Jauch-Lembach, Julia, Thakur, Anjali, Haliduola, Halimuniyazi, Brueckmann, Ines, Gaylis, Norman B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669771/
https://www.ncbi.nlm.nih.gov/pubmed/33119861
http://dx.doi.org/10.1007/s40259-020-00447-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669771/
https://www.ncbi.nlm.nih.gov/pubmed/33119861
http://dx.doi.org/10.1007/s40259-020-00447-6

Ejemplares similares